Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
Completed · Phase 1 · Has a placebo group
Conditions studied: RSV Infection
In brief
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of recombinant, live-attenuated respiratory syncytial virus (RSV) vaccines (RSV 6120/∆NS1 or RSV 6120/F1/G2/∆NS1) in RSV-seropositive children 12 to 59 months of age and RSV-seronegative infants and children 6 to 24 months of age.
Key facts
- Study ID
- NCT03596801
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 60
- Starts
- 2018-06-29
- Expected to finish
- 2024-04-25
- Last updated by the study team
- 2026-02-13
Who can join
Age: 1 and older, up to 5. Sex: any. Healthy volunteers: accepted.
Where it is running
- Johns Hopkins University Center for Immunization Research — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.